Aurinia Pharmaceuticals $AUPH will be the stock to watch out for on Friday. Shares surged in aftermarket hours on Thursday after it announced positive results from Phase 2b clinical trial, AURA-LV, evaluating voclosporin for the treatment of lupus nephritis (LN), inflammation of the kidney caused by systemic lupus erythematosus. The positive data comes after strong results reported in Augus